Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying different ways to manage male patients with hemophilia A who have developed inhibitors to factor VIII FVIII treatment. Hemophilia A is a serious bleeding disorder caused by a lack of FVIII, leading to frequent bleeding episodes and joint damage. Some patients develop inhibitors that reduce the effectiveness of FVIII replacement therapy. This observational study aims to document current immune tolerance induction ITI methods and evaluate the safety and effectiveness of ITI, including when combined with emicizumab, a newer therapy. Participants will be grouped based on their treatments one group receives ITI with Nuwiq, octanate, or wilate, with bypassing agents like aPCC or rFVIIa as needed another group receives ITI combined with emicizumab and bypassing agents the third group receives routine prophylaxis with emicizumab or bypassing agents without ITI. Treatment doses are decided by the investigators based on patient condition. Participants may switch groups if their treatment changes and will be observed for up to five years. Throughout the study, participants will be monitored for inhibitor levels, FVIII recovery and half-life, and annual bleeding rates. Researchers will also track the use and frequency of emicizumab and bypassing agents, bleeding severity, surgical bleeding, adverse reactions, thrombotic events, and treatment costs. Data collection will occur regularly over the five-year period to understand long-term outcomes and safety.